Search





Search





Markets
/
Stocks
/
artl
/

Artelo Biosciences Inc

ARTL

Add to Watchlist

0.766USD

+0.011+1.40%

Close 07-31 16:00（ET）Quotes delayed by 15 min

515.39KMarket Cap

LossP/E TTM

Artelo Biosciences Inc

0.766

+0.011+1.40%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+1.40%

5 Days

-24.92%

1 Month

-30.38%

6 Months

-85.07%

Year to Date

-79.08%

1 Year

-93.54%

Key Figures

--Open

0.820High

127.99KVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

19.02%Turnover Ratio

0.755Prev. Close

0.750Low

79.58KTurnover

LossP/E Static

0.08P/B

0.00%Div Yield TTM

-167.97%ROA

85.80052wk High

0.70Volume Ratio

-9.83MNet Profit

673.01KShares

-28.5377EPS TTM

-0.09Beta

-367.70%ROE

1.19052wk Low

9.27%Amplitude

--Gross Margin

515.39KMarket Cap

-4.59Reward/Risk

6.97%Risk Rate

TradingKey Stock Score of Artelo Biosciences Inc

Currency: USD Updated: 2026-07-30

Key Insights

Artelo Biosciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 161 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 30.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Artelo Biosciences Inc's Score

Industry at a Glance

Industry Ranking

161 / 384

Overall Ranking

240 / 4280

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Artelo Biosciences Inc Highlights

StrengthsRisks

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.03, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 34.88K shares, increasing 22.85% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.72.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

30.000

Target Price

+471.43%

Upside Space

Artelo Biosciences Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 1 analysts

Hold

Current Rating

30.000

Target Price

+471.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

496

Total

Median

Average

Company name

Ratings

Analysts

Artelo Biosciences Inc

ARTL

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

Kymera Therapeutics Inc

KYMR

...

Indicators

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Sell

RSI(14)

25.773

Sell

STOCH(KDJ)(9,3,3)

11.043

Oversold

ATR(14)

0.087

Low Volatility

CCI(14)

-133.793

Sell

Williams %R

87.883

Oversold

TRIX(12,20)

-1.176

Sell

StochRSI(14)

42.199

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.828

Sell

MA10

0.953

Sell

MA20

1.018

Sell

MA50

1.190

Sell

MA100

2.956

Sell

MA200

3.308

Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Artelo Biosciences Inc Info

Ticker SymbolARTL

CompanyArtelo Biosciences Inc

CEOGorgas (Gregory D)

Websitehttps://artelobio.com/

Shareholders

Shareholders

Proportion

Intracoastal Capital, L.L.C.

8.63%

Kathmere Capital Management

1.41%

Jane Street Capital, L.L.C.

1.39%

Matsui (Connie L)

1.25%

Vanguard Capital Management, LLC

1.08%

Other

86.23%

Popular Instruments

FAQs

What is the current price of Artelo Biosciences Inc (ARTL)?



The current price of Artelo Biosciences Inc (ARTL) is 0.77.

What is the symbol of Artelo Biosciences Inc?



The ticker symbol of Artelo Biosciences Inc is ARTL.

What is the 52-week high of Artelo Biosciences Inc?



The 52-week high of Artelo Biosciences Inc is 85.80.

What is the 52-week low of Artelo Biosciences Inc?



The 52-week low of Artelo Biosciences Inc is 1.19.

What is the market capitalization of Artelo Biosciences Inc?



The market capitalization of Artelo Biosciences Inc is 515.39K.

Is Artelo Biosciences Inc (ARTL) currently rated as Buy, Hold, or Sell?



According to analysts, Artelo Biosciences Inc (ARTL) has an overall rating of signal_hold, with a price target of 30.00.

What is the Earnings Per Share (EPS TTM) of Artelo Biosciences Inc (ARTL)?



The Earnings Per Share (EPS TTM) of Artelo Biosciences Inc (ARTL) is -37.55.